Abstract：Objective To investigate the effect of Piperacillin-Tazobactam combined with Amikacin on patients with bronchiectasis and infection.Methods The clinical data of 198 patients with bronchiectasis-associated infection who treated in our hospital from February 2016 to August 2018 were selected.According to different therapeutic methods,they were divided into the control group (treated with Etimicin Sulfate, n=98) and the observation group (Piperacillin-Tazobactam combined with Amikacin, n=100).The disappearance time of cough and expectoration, the time of body temperature returning to normal, disappearance time of hemoptysis were observed between the two groups.In addition,the forced expiratory volume 1 second before and after treatment (FEV1), forced vital capacity (FVC) and FEV1/FVC were also observed as well as the clinical efficacy.Results The time of cough and expectoration disappeared, the time of body temperature returned to normal, and the time of hemoptysis disappeared in the observation group were shorter compared with those in the control group with statistical significance (P<0.05）.There was no significant difference in FEV1, FVC and FEV1/FVC between the two groups before treatment.After treatment, the FEV1, FVC and FEV1/FVC in the control and observation groups were all higher than those before treatment, respectively.The FEV1, FVC and FEV1/FVC in the observation group after treatment were all higher compared with those in the control group (P<0.05).The total clinical effectiveness rate in the observation group was higher than that of the control group, the difference was statistically significant (P<0.05）.Conclusion Piperacillin-Tazobactam combined with Amikacin in the treatment of patients with bronchiectasis and infection can shorten the improvement time of clinical symptoms, enhance the lung function and clinical efficacy, and is worthy of clinical application.
京公网安备 11010502046607号